[Vectorization of antineoplastic drugs by low density lipoproteins: incorporation of acyl celiptium and metabolism of complexes in the cellular receptor of human fibroblasts].
Samadi-Baboli
M
M
Faculté des Sciences Pharmaceutiques, Université Paul-Sabatier, Toulouse, France.
Favre
G
G
Soula
G
G
D000470:Alkaloids / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000378:metabolism*; D002478:Cells, Cultured; D004337:Drug Carriers; D004611:Ellipticines / Q000378:metabolism*; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism*; D011973:Receptors, LDL / Q000378:metabolism*
D000470:Alkaloids; D000970:Antineoplastic Agents; D004337:Drug Carriers; D004611:Ellipticines; D008077:Lipoproteins, LDL; D011973:Receptors, LDL; C027767:elliptinium
Vectorisation de médicaments anticancéreux par les lipoprotéines de basse densité (LDL): incorporation d'acyl celiptium et métabolisme des complexes vis-a-vis du récepteur cellulaire des fibroblastes humains.